EGFL7 Inhibitors
EGFL7, a crucial regulator of angiogenesis, is the focus of targeted modulation through various chemical inhibitors, each classified as either direct or indirect based on their distinct mechanisms of action. Direct inhibitors, exemplified by Tivozanib and Axitinib, operate by directly binding to specific kinases integral to EGFL7 signaling pathways. Through this direct interaction, these inhibitors disrupt the kinase-mediated activation of EGFL7, resulting in the attenuation of downstream cellular responses associated with angiogenesis. The precise targeting of kinases directly involved in EGFL7 signaling underscores the strategic approach of these direct inhibitors in modulating angiogenic processes.
In contrast, indirect inhibitors, such as AZD4547 and Nintedanib, take a more upstream or parallel route in their inhibitory effects by targeting kinases adjacent to EGFL7 in the signaling cascade. This indirect modulation of EGFL7 activity reflects the intricate regulatory network governing angiogenesis, wherein alterations in upstream kinases reverberate down to influence EGFL7-mediated cellular responses. The nuanced mechanisms of these indirect inhibitors highlight the complexity of the molecular interactions governing angiogenic pathways. Additionally, inhibitors like Vandetanib and Sorafenib broaden the scope of their action by targeting kinases involved in vascular endothelial growth factor receptor (VEGFR) signaling. Through this broader-spectrum targeting, these inhibitors intersect with pathways associated with EGFL7, indirectly influencing its activity. This multifaceted approach to kinase inhibition demonstrates the interconnected nature of angiogenic signaling pathways and the adaptability of chemical inhibitors in modulating various components of these intricate networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tivozanib | 475108-18-0 | sc-475339 | 5 mg | $320.00 | ||
Tivozanib (VEGFR Tyrosine Kinase Inhibitor IV) acts by binding to and blocking the ATP-binding site of receptor tyrosine kinases, including those involved in EGFL7 signaling pathways. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with inhibitory activity against EGFL7. It disrupts EGFL7-mediated signaling by targeting key kinases involved in its pathways. By interfering with the activity of these kinases, sunitinib directly inhibits EGFL7 and modulates its cellular functions. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is a selective inhibitor of fibroblast growth factor receptor (FGFR) kinases, which are implicated in EGFL7 signaling pathways. By blocking FGFR kinases, AZD4547 indirectly inhibits EGFL7 function. The disruption of FGFR-mediated signaling cascades results in the modulation of EGFL7 activity, making AZD4547 an indirect inhibitor of EGFL7. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF1120 (Nintedanib) is a triple angiokinase inhibitor that indirectly affects EGFL7 by targeting various kinases involved in angiogenesis. It modulates signaling pathways associated with EGFL7, leading to downstream effects on its activity. Nintedanib's indirect inhibition of EGFL7 is a consequence of its broad-spectrum action on kinases that play crucial roles in EGFL7-mediated cellular processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that indirectly influences EGFL7. It primarily targets Bcr-Abl, c-Kit, and PDGF receptors, among others. Through the inhibition of these kinases, imatinib impacts signaling pathways linked to EGFL7, resulting in the modulation of EGFL7 activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor that indirectly influences EGFL7 by targeting kinases involved in vascular endothelial growth factor receptor (VEGFR) signaling. By blocking these kinases, vandetanib modulates the downstream pathways that intersect with EGFL7-mediated processes. The indirect inhibition of EGFL7 by vandetanib is a consequence of its impact on kinases that converge on common signaling cascades involving EGFL7. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor with inhibitory activity against kinases involved in angiogenesis, including those associated with EGFL7 signaling. By blocking these kinases, regorafenib indirectly influences EGFL7 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that indirectly influences EGFL7 by targeting kinases involved in angiogenesis, such as VEGFR and PDGFR. The inhibition of these kinases by sorafenib leads to downstream effects on EGFL7 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that indirectly influences EGFL7 by targeting kinases such as Bcr-Abl and Src family kinases. Through the inhibition of these kinases, dasatinib impacts signaling pathways linked to EGFL7, leading to the modulation of EGFL7 activity. The indirect inhibition by dasatinib is a consequence of its interference with kinases upstream or parallel to EGFL7-mediated pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
XL-184 free base (Cabozantinib) is a multi-kinase inhibitor with inhibitory activity against kinases involved in angiogenesis, including those associated with EGFL7 signaling. By blocking these kinases, cabozantinib indirectly influences EGFL7 activity. | ||||||